FDA approves Vyvanse generics for ADHD, binge-eating disorder

The FDA has approved multiple first generics of Vyvanse capsules and chewable tablets for ADHD in patients aged 6 years and older, as well as for moderate to severe binge-eating disorder in adults.

According to an FDA press release, generic medicines approved by the FDA work in the same way and provide similar benefits and risks as their brand-name counterparts.

Vyvanse (lisdexamfetamine dimesylate, Takeda Pharmaceuticals) was approved in 2007 for treating ADHD and in 2015 for binge-eating disorder.

Vyvanse generics were approved in capsule form in seven doses ranging from 10 mg to 70 mg, while chewable tablets were approved in six doses ranging from 10 mg to 60 mg, per the FDA’s website.